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Endemic fluorosis - a
model for studies examining
the effect of fluoride on bone
S C Honiball, R Blaauw, R Martell, J J OF Taljaard,
J M Slokol, F S Hough
The use of fluoride in the treatment of osteoporosis is
complicated by concerns about the integrity of the newly
fonned bone, as well as the fact that not all patients
respond to the drug. In an attempt to broaden insight into
the varied skeletal response to fluoride exposure, we
studied (clinical, dietary analysis, radiology, biochemistry
and genetic markers) all114 pennanent inhabitants of an
endemic fluorosis area. Unequivocal radiological evidence
of osteofluorosis was present in 26% of subjects, while
48% had nonnal skeletal radiological results and 4% were
found to be osteopenic. Twenty-two per cent were
unclassifiable. Individuals with fluorosis were older and
predominantly male, Although musculoskeletal symptoms
occurred more frequently in patients with osteofluorosis,
these subjects did not have an increased fracture
prevalence and were, in fact, found to have a higher
metacarpal as well as femoral cortical bone mass. In
subjects with osteofluorosis, the average fluoride intake
and residency in the area were similar to those of
unaffected Kenhardt individuals, implying that there are
causative factors other than fluoride exposure. Moreover,
renal excretion of fluoride was comparable, as was the
average energy, protein, mineral and alcohol intake. Mean
serum calcium, phosphate, alkaline phosphatase,
parathyroid honnone, calcitonin and 25-hydroxyvitamin 0
levels were unremarkable and similar in subjects with and
without osteofluorosis. However, a family tree analysis of
the population revealed that 4 very closely related
subjects had osteopenia, which suggests that a genetic
predisposition may at least partially explain why the
skeletal response to fluoride is not determined by fluoride
exposure alone.
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The use of fluoride in the management of osteoporosis has
been a source of controversy since it was first suggested by
Rich and Ensinck' more than 3 decades ago. Clinical studies
have produced extensive evidence to support the contention
that fluoride is one of the most effective agents available to
increase spinal bone density over a sustained period?
Treatment is, however, not without pitfalls and a definite
proportion of patients (15 - 30%) do not respond to the
drug.] It has been suggested that failure to respond may be
due to intestinal malabsorption and/or impaired skeletal
uptake of fluoride_~This does not, however, explain the
phenomenon, since responders and non-responders have
been shown to have comparable blood fluoride levels during
treatment. Apart from a recent report documenting higher
urinary fluoride levels in responders,5 no clear reason for this
apparent individual sensitivity has yet been identmed.
In osteoporotic patients responding to fluoride therapy,
the beneficial mitogenic effect is dose-dependent and linear
with time during continuous administration.6 Fluoride has
been shown to increase the birth rate and number of
osteoblasts, the rate of bone formationT and the synthesis of
alkaline phosphatase and osteocalcin. 1•a However, a 'toxic'
effect at the individual osteoblastic cell level, as evidenced
by a reduction in osteoblastic activity and a delay in
mineralisation, has been well established.9 Moreover, sodium
fluoride has been associated with a painful lower-extremity
syndrome believed to represent an imbalance between
matrix production and mineralisation, leading to micro-
fractures.'o Some studies have suggested that fluoride
increases trabecular connectivity and strength,l1 whereas
others reported the failure to induce de novo generation of
trabeculae or the restoration of connectivity.12 Effects on
cortical bone are less marked, and it has been suggested
that fluoride-induced remodelling could increase intracortical
porosity and may enhance the risk of future fracture. '3
Recently, Riggs and co-workers14 reported a 30% increase
in spinal bone mass, but a significantly increased rate of
non~vertebral(including hip) fractures after fluoride therapy.
Although these findings have since been refuted by several
studies and generally ascribed to differences in fluoride bie-
availability and/or the dose employed,15 some concern about
fracture prevalence in fluoride-treated patients still remains.
In an attempt to gain a better understanding of the
underlying reasons for the varied skeletal response to
fluoride exposure, we studied an area of endemic fluorosis
which is situated in the Kenhardt district of the Northern
Cape Province.
Patients and methods
AJI procedures for this study were approved by the
Institutional Review Board and Ethics Committee of the
Stellenbosch University Medical School and informed
consent was obtained from each subject. All the permanent
inhabitants (50 males and 64 females, aged 6 - 70 years) of
an isolated community resident in the endemic fluorosis
district of Kenhardt, situated some 700 km north-west of
Cape Town, were studied. This population is of low socio-
economic and educational background. The fluoride content
of the only drinking water supplying this village (bore-holes)
was shown to be 6.2 mg/I, which greatly exceeded the
accepted safe level of 1 mg/L Individuals were subjected to
a detailed history and full clinical examination, which took
due cognisance of previously reported manifestations
associated with excessive fluoride ingestion, e.g. bone or
joint pain and tenderness, spine or long-bone deformities,
arthritis, calcifications. la None of the subjects had previously
received any treatment for bone diseases. A dietary analysis
of all subjects, performed by a qualified dietician, included a
quantified food frequency questionnaire on habitual food
intake during the month preceding the study. Portion sizes
were standardised by the local Research Institute for
Nutritional Diseases and the reproducibility of data obtained
from the questionnaire was verified before use in this study.
Current as well as previous alcohol and nicotine
consumption were also documented.
The radiological evaluation of each patient included a
postero-anterior and lateral view of the chest, thoracic and
lumbar spine, the pelvis (inclUding the proximal third of each
femur) and both hands. Appendicular bone mass was
quantified by radiogrammetry of the second metacarpal, the
Singh index and measurements of the calcar femorale.H
Previously reported radiological manifestations of
osteofluorosis, ,a such as increased bone density, coarsened
trabeculations, hypertrophic changes, ligarnentous
calcifications and signs of secondary hyperparathyroidism or
osteomalacia, were also documented. Subjects with
osteofluorosis were further divided into those with moderate
and those with severe disease, based on the degree of bony
sclerosis. All radiographs were evaluated by two
independent observers and skeletal radiology formed the
basis of this comparative study between patients with and
without fluorosis.
Fasting serum calcium (total), phosphate, alkaline
phosphatase (ALP), creatinine, electrolytes and liver function
profiles were determined by SMAC (Technicon Autoanalyzer,
Basingstoke, UK). The serum calcium concentration was
corrected to a plasma albumin level of 40 g/I (0.02 mmoVI
calcium per g/I albumin). The serum magnesium level was
measured calorimetrically (Bio Merieux, E~gland). A double
antibody sequential competitive radio immunoassay kit was
used to measure cirCUlating calcitonin (Diagnostic Products
Corporation, USA), and for immunoreactive parathyroid
hormone a C-terminal assay with the antibody directed at
the 65 - 84 sequence of human iPTH was used (Immuno
Nuclear Corporation, USA). Serum 25-hydroxyvitamin 0 was
determined by a competitive protein-binding assay,
employing a rat kidney receptor, after rapid lipid extraction
and preliminary purification of serum on a C18 Sep-Pak
cartridge, followed by purification on a silica Sep-Pak with
hexane isopropanol. '8
Urinary calcium and creatinine were measured with an
Astra system (Beckman, USA). An ion-selective electrode
(Orion Model 94-09; Orion Research Inc., Cambridge, USA)
was used to measure fluoride in the drinking water and
urine.
A family tree analysis of the entire population was
performed and a limited number of specific genetic markers
were determined. HLA typing was performed by means of a
standard microlymphotoxicity technique. The ABO, MNSs,
Rh, and FY blood groups were tested using standard
serological methods.





Results were analysed by means of a two-sample t-test or
analysis of variance when more than two groups were
compared. Lad scores were estimated with the L1PED
computer programme.
Results
The fluoride content of the drinking water was found to be
6.2 mg/I, which is six times higher than the accepted safe
level of 1 mgll. These high fluoride levels did not, however,
uniformly produce radiological bone changes in the
population.
We have previously established normative
radiogrammetric data for metacarpal cortical measurements
in our local populations.4'Il In the present study individuals
with moderate and severe osteofluorosis were found to have
a higher cortical bone mass than their unaffected
counterparts who displayed a regular distribution of
metacarpal cortical thickness (Fig. 1). Normal calcar
femorale measurement values for children are not available
and evaluation of this parameter and the Singh index were
therefore limited to the adult study population. Assessment
of the Singh index and thickness of the calcar femorale did
not differ markedly between subjects with normal and
moderately sclerotic radiographs but both were
significantly higher in patients with severe osteofluorosis
(Table I).
NORDIN INDEX
Fig. 1. Metacarpal cortical thickness (MeT) or Nordin index of
patients with normal radiographs, moderate and severe
osteofluorosis. The MeT of subjects with severe osteofluorosis
differed significantly (P < 0.01) from that of individuals with
normal radiographs.
Radiology
Skeletal radiology, assessed by two independent observers
without prior knowledge of the subject matter, formed the
basis for further comparison between normal, f1uorotic and
osteopenic subjects. Clear radiological evidence of
osteosclerosis (causes other than fluoride excess excluded,
e.g. Paget's disease of bone, skeletal dysplasias) was
present in 26% of subjects, while 48% had normal skeletal
radiology. Four per cent of the population was osteopenic
with evidence of vertebral translucency and deformities
(biconcavity, wedging or compression of more than 20%),'5
while the remaining 22% could not be classified with
certainty as either normal or affected; these probably largely
represented subjects with early fluorosis, but were not
included for further comparison. The 5 osteopenic SUbjects
were all female, and 4 were closely related, viz. a mother
aged 65 years, two daughters (44 and 46 years) and a
granddaughter (24 years). With the exception of rib fractures
in 2 osteofluorotic patients and vertebral fractures in
osteopenic individuals, no signs of skeletal fractures or
osteomalacia were detected in any subject. Osteosclerotic
individuals were, furthermore, classified as having either
moderate or severe disease. Ugamentous calcification,
hypertrophic changes and bony overgrowth were almost
entirely confined to those with severe osteosclerosis.
4.4 ± O.3§










Total 6.2 ± 0.3
Singh index (scored from' to 6)
Males 5.3 =0.3 5.6 ± 0.2
Females 5.2 ± 0.2 5.6 ± 0.2
Calcar femorale (mm)
Males 6.8 ± 0.5
Females 6.1::: 0.3
Darn are presented as the mean := SEM.
• Normal v. severe osteofluOfOSis (P < O.ooot).
t Normal v. osteopenia (P < 0.05).
i: Normal v. model"ate osteofluorosis (P" 0.0184).
1] Normal v. severe osteofluorosis (P < 0.0001).
§ NotmaJ v. osteopenia fP '" 0.0054).
Normal Moderate Severe
radiographs osteoftuorosis osteofluorosis Osteopenia
Table I. Singh index and thickness of the calcar femora le in adults
with normal, fluorotic or osteopenic skeletal radiology
Clinical data
Clinical and biochemical data on all 29 individuals assessed
with radiological osteofluorosis were compared to those of
the 55 subjects with normal skeletal radiology.
Affected individuals were older and predominantly male
(fable 11), although children as young as 6 - 8 years were
found to be severely osteosclerotic. In subjects with
fluorosis the average fluoride intake, residency in the area
and years of exposure were similar to those of unaffected
controls, implying that causative factors other than fluoride
exposure alone exist (Table 11). Musculoskeletal symptoms
(e.g. bone pain, arthralgia, joint pain) and clinical signs (bone
tenderness, arthritis, synovitis, kyphoscoliosis, genu varum,
genu valgum, tibial bowing) were more prevalent in patients
with osteofluorosis, especially the older subjects with severe
disease, although a history of skeletal fracture or the
presence of dental fluorosis occurred as commonly in
subjects with normal skeletal radiology.
There were no significant differences in the daily intake of
nutrients (expressed as a percentage of recommended daily
allowance) between normal and fluorotic subjects. The
calcium intake was low, but comparable between groups,
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Table Ill. Dietary history
Dietary intake (% of RDA)
Table 11. Clinical data
Normal
radiographs Osteofluorosis
(N = 55) (N = 29)
Age (yrs) 31 ± 4 40 ± 6
Gender (male/female) 1:2 7:3
Fluoride exposure
Fluoride intake (mglday) 9.1.0.7 9.9 ± 0.8
Residency in area
(% of lifetime) 69 ± 5 71 ± 5
Total years of exposure (yrs) 22.3 28 ±4
Clinical signs and symptoms
(% of subjects affected)
Dental fluorosis 100 100
Musculoskeletal symptoms 23 100
Clinical skeletal abnormalities 17 77
Data are presented as the mean ~ SEM.
Normal radiographs Osteofluorosis
Table IV. Biochemical data
Normal Osteosclerosis
radiographs Moderate Severe
(N=55) (N= 18) (N = 11)
Serum
Corrected calcium
(mmoVl) 2.30 ± 0.01 2.36.0.01 2.34.0.01
Phosphate (mmol/l) 1.16.0.07 1.14±O.14 1.18.0.12
Magnesium (mmol/l) 0.83.0.07 0.82 ± 0.06 0.84.0.07
Alkaline phosphatase
(U/L) 104 ± 5 104 ± 6 133 ± 16
Creatinine (jJmoVI) 85.2 77 .5 82 ± 4
Parathyroid hormone
(pmolll) 49.5.3.7 45.9.5.1 46.0 ± 2.9
Calcitonin (pmol/l) 7.0.0.6 6.5.0.3 6.5.0.3
25-hydroxyvitamin 0
(ngimij 22.4.0.5 21.9.0.8 17.1.1.7"
Urine
Calcium/creatinine
(mmoVrnmol) 0.27.0.01 0.29.0.02 0.28.0.02
Fluoride (Ilmolll) 447 ± 38 451 •.36 474.61
FlUOride/creatinine
(l.JmoVmmoQ 52.7.2.7 58.3 ± 2.8 57.5±5.1
Data are presented as me mean =SEM.













Data are presented as the meal1 ~ SEM.
Biochemistry
The serum levels of corrected calcium. phosphate and
magnesium were normal and comparable between groups,
while the mean total serum ALP level was modestly raised in
all subjects, more pronounced in those with severe
osteofluorosis, although this did not reach statistical
significance (fable IV). Ukewise, the urinary excretion of
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Calciotropic hormones
The concentrations of the calciotropic hormones.
parathyroid hormone (PTH) and calcitonin, were similar, but
25-hydroxyvitamin 0 levels were significantly, albeit
modestly, lower in subjects with severe osteofluorosis
(Table IV).
Fig. 2. Partial family tree which includes 4 of the 5 osteopenic
subjects in the entire study population.
Discussion
Genetic markers
A family tree analysis of the entire population revealed that
individuals belonged to one of five large families.
Osteofluorotic individuals were more prevalent in some
families and the genetic model proposed was one of
dominant inheritance with incomplete penetrance.
Furthermore. of the 5 individuals who were radiologically
osteopenic, 4 were closely related: a mother. 2 daughters
and a granddaughter (Fig. 2). Unkage of a putative locus for
susceptibility or resistance to the development of fluorosis
could be excluded at the HLA locus and was indeterminate
at the other marker loci examined.
We investigated the entire permanent population of an area
of endemic fluorosis in order to highlight selected aspects of
this condition and in an attempt to extrapolate conclusions
to some of the clinical problems encountered in the
treatment of osteoporotic patients with fluoride. Owing to
the remote location of the area, osteodensitometric
techniques to assess appendicular as well as axial bone
mass could not be employed. and standard radiology
formed the basis for comparison between normal. f1uorotic
and osteopenic subjects. The fluoride content of the
drinking water was found to exceed greatly the accepted
safe level of 1 mg/l, yet did not uniformly produce
radiological bone changes. Despite the long-term excessive
ingestion of fluoride in all the subjects. only 26% of the




population had clear radiologically detectable skeletal
changes.
Clinical features were nonspecific, essentially confined to
the musculoskeletal system, and not very helpful in
predicting the presence of fluorosis in an individual subject.
Dental mottling was present in all subjects, probably due to
the fact that SUbjects were exposed to fluoride during the
period of tooth formation. There was no association
between the degree of dental and skeletal involvement.
Clinical manifestations included bone pain, joint pain and
swelling and bowing of the femora or tibiae. These findings
were more prevalent in, although not exclusive to, subjects
with severe fluorosis. Evidence of ligamentous and soft-
tissue calcification, previously suggested to be common
early features of osteofluorosis,'~.1·was only detected in
cases of advanced disease in the present study. An
increased radiological bone density was found to be the
only typical early change.
Some of the more controversial aspects of fluoride
therapy in osteoporosis concern the structural integrity of
the newly formed bone - specifically the induction of a
mineralisation defect - and the possibility that fluoride-
induced remodelling could increase intracortical porosity
with consequent cortical thinning and an increased fracture
risk.l(H~ In this study, no radiological signs of osteomalacia
were detected in any subject. Serum levels of calcium,
phosphate, ALP and PTH were normal and similar in
subjects with and without osteofluorosis. Moreover, f1uorotic
patients did not have an increased fracture prevalence and
were, in fact, found to have an increased metacarpal as well
as femoral cortical bone mass.
The varied skeletal response to fluoride exposure,
preViously documented in osteoporotic patients treated with
this agents and in endemic fluorosis populations,ll was
confirmed in our study. Conceivably, the underlying
mechanism of this individual susceptibility could involve
either differences in the pharmacobiology of fluoride and/or
the skeletal response to the agent. It is known that the
amount of bio-available ionic fluoride in the body depends
on the quantity of ingested fluoride and its passive
absorption from the gastro-intestinal tract. Fluoride follows
only two post-absorptive pathways, viz. urinary excretion of
the majority, and skeletal uptake of the remainder by
incorporation into the hydroxy-apatite crystal lattice of bone.
Calcified tissue is therefore Virtually the only retention site for
fluoride.22 Although it has been suggested that failure to
respond may be due to intestinal malabsorption of fluoride
and/or its impaired skeletal uptake, little evidence exists to
support this hypothesis.23 It has been shown, in an area of
endemic fluorosis, that the fluoride content of the drinking
water correlated with the fluoride content of bone,l~ and
Marcelli et a/.25 recently reported that the bone fluoride
content was not significantly higher in responders than in
non-responders after 2 years of fluoride therapy. In our
study popUlation the fluoride content of the drinking water
was six times higher than the accepted safe level. In
subjects with osteofluorosis, the average fluoride intake and
duration of residence in the area were similar to those of
unaffected controls, implying that causative factors other
than fluoride exposure exist. Moreover, renal excretion of
fluoride was similar in affected and normal individuals. The
rapid uptake of f1uorine-18 has been shown to occur in bone
sites where calcium accretion is the most active.llI Bone
changes induced by fluoride may therefore depend not only
on the dose received, but also on the level of bone
turnover.22 One could therefore assume that fluoride uptake
may be higher in younger individuals with an active
modelling (child) or remodelling (younger adult) skeleton.
However, since fluoride can, in itself, stimulate bone
formation, and thus calcium accretion, it is likely that it
augments its own uptake,v In our study population, we
found responders and non-responders throughout the entire
age spectrum. In an endemic fluorosis area in Finland, males
and females were affected equally,2~ while in a group of
osteoporotic patients treated with sodium fluoride, males
increased their bone mineral density significantly more than
females (6.3% v. 3.8% per year) during the first 18 months
of follow-up.3 In the Kenhardt population men and women of
all ages were affected, males haVing a higher prevalence of
skeletal involvement.
A number of biochemical changes have been noted during
treatment with fluoride. Serum ALP and osteocalcin levels
tend to increase and although intestinal calcium absorption
remains unaltered, a decline in its urinary excretion has been
demonstrated, a finding attributed to the skeletal retention of
calcium induced by fluoride.l ! Recently Stamp et al. reported
that non-responders to fluoride therapy were characterised
by low serum ALP and phosphate, and increased serum
PTH and urinary calcium levels.29 In the Kenhardt population
mean serum ALP was higher in patients with severe
fluorosis, but serum calcium, phosphate, PTH and urinary
calcium excretion were comparable.
Previous reports in patients,JO as well as experimental
animal models,31 have suggested that a low dietary intake of
calcium may predispose to the development of fluorosis.
These findings could not be confirmed in our study, where
the calcium intake was low in the entire population,
responders and non-responders alike. Serum calcium and
urinary calcium excretion were also similar in all groups.
Serum 25-hydroxyvitamin 0 levels were modestly, albeit
significantly, lower in subjects with severe osteofluorosis but
identical in those with moderately osteosclerotic and normal
skeletal radiographs. Mean 25-hydroxyvitamin 0 levels in all
groups were however well within the normal range. Although
we cannot rule out abnormalities of calcium homeostasis as
a concomitant causative factor, this possibility would seem
unlikely.
Perhaps the most interesting finding of this study was the
observation that the individual susceptibility of skeletal
tissue to fluoride may have a genetic basis. Despite
exposure to excessive amounts of fluoride, 5 individuals
were found to be osteopenic, 4 of whom were very closely
related. This observation suggested that the skeletal
response to fluoride may be partly genetically determined.
The possibility that the osteopenia could have been
determined by a separate gene (e.g. for osteogenesis
imperfecta or the vitamin 0 receptor) can, however, not be
excluded. Unkage of a putative locus for susceptibility or
resistance of the skeleton to fluoride could not be
established by a limited number of genetic markers
employed in this study. We conclude that a genetic basis for
the varied osteoblastic response to fluoride exposure may
exist and deserves further study.
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developing a practice premises
managing staff and team building
records and computers
management structure
As well as comprehensive coverage of the practical
housekeeping issues. advice and tips are also given
on managing the chronic administration overload
and coping with the continual change in the
organisation of general practice. This book also
reflects the current business demands on all GPs.
and tackles the issues of business planning and
profitability in a way relevant to both fundholders
and non-fundholders. Other subjects covered
include:
This user friendly, practical guide addresses all the
non-clinical aspects of the day to day running of a
general practice. which can intimidate both
newcomers and old hands alike.
\Vritten by a senior partner with extensive
experience in general practice. this guide will be an
indispensable introduction for general practice
registrars. new GPs. and trainee practice
management staff, as well as offering new
perspectives and insights to established GPs.
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